Biotechnology Letters

, Volume 40, Issue 5, pp 789–795 | Cite as

A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index

  • Yun Yang
  • Rui Guo
  • Qi Chen
  • Youxun Liu
  • Pengfei Zhang
  • Ziheng Zhang
  • Xi Chen
  • Tianyun Wang
Original Research Paper
  • 115 Downloads

Abstract

Objective

To promote targeting specificity of anti-CD47 agents, we have constructed a novel bispecific antibody fusion protein against EGFR and CD47, which may minimize the “off-target” effects caused by CD47 expression on red blood cells.

Results

The novel bispecific antibody fusion protein, denoted as Bi-SP could simultaneously bind to EGFR and CD47 and exhibited potent phagocytosis-stimulation effects in vitro. Bi-SP treatment with a low dose more effectively inhibited tumor growth than either EGFR-targeting antibody, Pan or the SIRPα variant-Fc (SIRPαV-Fc) in the A431 xenograft tumor model. In addition, the treatment with Bi-SP produced less red blood cell (RBC) losses than the SIRPαV-Fc treatment, suggesting its potential use for minimizing RBC toxicity in therapy.

Conclusions

Bi-SP with improved therapeutic index has the potential to treat CD47+ and EGFR+ cancers in clinics.

Keywords

Bispecific antibody fusion protein CD47 EGFR Phagocytosis Therapeutic index 

Notes

Acknowledgements

We thank Binfeng Cheng, Huaizu Guo and Jin Xu for their expert technical assistance. This work was supported by grants from the Natural Science Foundation of China (81703054, 81403161, 21605074), National Training Program of Innovation for Undergraduates (201710472029), Key scientific research project of higher education of Henan Province, China (17A350012), Key Science and Technology Program of Henan Province, China (172102310614), Doctoral Foundation of Xinxiang Medical University (XYBSKYZZ201506).

References

  1. Chao MP et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699–713.  https://doi.org/10.1016/j.cell.2010.07.044 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Dheilly E et al (2017) Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther 25:523–533.  https://doi.org/10.1016/j.ymthe.2016.11.006 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Fauvel B, Yasri A (2014) Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer MAbs 6:838–851.  https://doi.org/10.4161/mabs.29089 PubMedGoogle Scholar
  4. Huang Y, Ma Y, Gao P, Yao Z (2017) Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. J Thorac Dis 9:E168–E174.  https://doi.org/10.21037/jtd.2017.02.30
  5. Junutula JR et al (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16:4769–4778.  https://doi.org/10.1158/1078-0432.CCR-10-0987 CrossRefPubMedGoogle Scholar
  6. Khandelwal S, van Rooijen N, Saxena RK (2007) Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 47:1725–1732.  https://doi.org/10.1111/j.1537-2995.2007.01348.x CrossRefPubMedGoogle Scholar
  7. Kwong LS, Brown MH, Barclay AN, Hatherley D (2014) Signal-regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity– implications for engraftment of human cells. Immunology 143:61–67.  https://doi.org/10.1111/imm.12290
  8. Liu B et al. (2017) Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. MAbs 1–10.  https://doi.org/10.1080/19420862.2017.1409319
  9. Liu X et al (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21:1209–1215.  https://doi.org/10.1038/nm.3931 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Matozaki T, Murata Y, Okazawa H, Ohnishi H (2009) Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 19:72–80.  https://doi.org/10.1016/j.tcb.2008.12.001 CrossRefPubMedGoogle Scholar
  11. Peipp M, Dechant M, Valerius T (2008) Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 20:436–443.  https://doi.org/10.1016/j.coi.2008.05.012 CrossRefPubMedGoogle Scholar
  12. Piccione EC et al. (2015) A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 7:946–956.  https://doi.org/10.1080/19420862.2015.1062192
  13. Shatz W et al (2013) Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 5:872–881.  https://doi.org/10.4161/mabs.26307 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, Hayes DF (1999) Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat 53:199–207CrossRefPubMedGoogle Scholar
  15. Weiskopf K, Weissman IL (2015) Macrophages are critical effectors of antibody therapies for cancer. MAbs 7:303–310.  https://doi.org/10.1080/19420862.2015.1011450 CrossRefPubMedPubMedCentralGoogle Scholar
  16. Weiskopf K et al (2013) Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88–91.  https://doi.org/10.1126/science.1238856 CrossRefPubMedGoogle Scholar
  17. Wiersma VR et al (2014) A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. Br J Haematol 164:304–307.  https://doi.org/10.1111/bjh.12617 CrossRefPubMedGoogle Scholar
  18. Willingham SB et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662–6667.  https://doi.org/10.1073/pnas.1121623109 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Xiao Z et al (2015) Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett 360:302–309.  https://doi.org/10.1016/j.canlet.2015.02.036 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Yang Y et al (2015) Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs 7:440–450.  https://doi.org/10.1080/19420862.2015.1008352 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Yang Y, Guo R, Tian X, Zhang Z, Zhang P, Li C, Feng Z (2017) Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer. Biochem Biophys Res Commun 489:523–527.  https://doi.org/10.1016/j.bbrc.2017.06.001 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  • Yun Yang
    • 1
  • Rui Guo
    • 2
  • Qi Chen
    • 3
  • Youxun Liu
    • 1
  • Pengfei Zhang
    • 1
  • Ziheng Zhang
    • 1
  • Xi Chen
    • 3
  • Tianyun Wang
    • 1
  1. 1.School of Basic Medical SciencesXinxiang Medical UniversityXinxiangPeople’s Republic of China
  2. 2.College of Biomedical EngineeringXinxiang Medical UniversityXinxiangPeople’s Republic of China
  3. 3.Sir Run Run Shaw Hospital, College of MedicineZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations